

MARA Rating®

COMPLIMENTARY REPORT ©MARA Rating Company AG® All rights reserved.

Ozureprubart

A Market Access Risk Assessment (MARA Rating®) of Ozureprubart for Food Allergy.




MARA
RATING COMPANY

MARKET ACCESS
RISK ASSESSMENT

MARA Rating® of Ozureprubart in Food Allergy.

Market Access Score

52/100



As of: **January-26**

Assets rated B+ have historically faced material challenges achieving broad reimbursement. Evidence or economic positioning has frequently raised affordability or value concerns during HTA assessment. This rating reflects positioning below commonly observed reimbursement thresholds, where access outcomes have often depended on restrictions, conditions, or population limitations. Broad access has been uncommon in comparable cases.

The **industry-standard MARA Rating®** synthesizes 10 payer-relevant evidence domains into a single market access risk score (A++ to C), calibrated against historical HTA outcomes.

MARA Rating® Heatmap for Ozureprubart

Clinical and Patient Value	Clinical Effectiveness	Safety & Adverse Events	Health-Related Quality of Life (HRQoL)
	Comparator Selection	Patient Population & subgroups	Evidence Quality & Robustness
Evidence and HTA Fit			
Economics and System Integration	Cost-Effectiveness	Resource Use and Cost	Care Pathway Integration

What You Unlock in the Full MARA Report

Structural drivers of access limitation

Detailed interpretation explaining why this asset faces high reimbursement barriers and which variables systematically constrain payer acceptance.

Benchmarking vs restricted-access peers

Comparison against assets with restricted or conditional reimbursement to clarify how similar profiles have been treated by HTA bodies.

Limits of evidence versus affordability

Clear separation of what evidence improvements typically do not resolve versus where pricing or population scope dominate outcomes.

Comparative radar and heatmap views

Visual positioning to assess how far this asset sits from reimbursement norms and where structural gaps are most pronounced.

The full MARA Report explains why this asset sits at its current rating level, which variables typically determine reimbursement outcomes at this level, and how comparable assets have performed in real reimbursement decisions.

Visit mararating.com to access the full report.

*Disclaimer: The MARA Rating® is an independent opinion of a drug's market access/pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. All opinions, analyses, and recommendations are statements of opinion, not statements of fact, and are supplied "as-is" without warranty of any kind, express or implied, including accuracy, completeness, or fitness for any particular purpose. Users assume full responsibility for their decisions and any consequences thereof. MARA Rating Company AG expressly disclaims all liability for any outcomes arising from the use of, or actions taken based on, this report. Report may contain public sector information and others. All brand names are the property of their respective owners. For reimbursement & HTA professionals only—Not for patients, prescribers or the general public. **Rights & Display.** © MARA Rating Company AG. Viewing permitted. Reproduction, reprinting, redistribution, scraping, or public display of any MARA rating, badge, letter grade, chart, or the "Primary line" in marketing, IR, PR, sales, paid media, conference materials, or websites is prohibited without a valid MARA Display License. Non-licensees may link to this page/report but may not copy, repost, or restyle our content. Use must include the as-of date, our one-line explainer, and no edits to wording or artwork. No composite marks (do not combine the MARA badge with other logos/seals). No implication of MARA's endorsement of efficacy, safety, price, or any transaction. "MARA", "MARA Rating", and the MARA badge are trademarks of MARA Rating Company AG. academic excerpt: up to 50 words of text (no badge/graphics) may be quoted with clear attribution and link. No commercial use. Misuse or corrections: contact sales@mararating.com.